Projects per year
Search results
-
Active
Improving safety and access to immune effector cell therapy with artificial intelligence technology???
NIH NATIONAL CANCER INSTITUTE (NCI)
2/1/24 → 1/31/26
Project: Research project
-
FT522-101: A Phase I Study of FT522 in Combination with Rituximab in Participants with Relapsed/Refractory B-Cell Lymphoma
5/17/23 → 5/31/28
Project: Research project
-
Off-the-Shelf Immune Effector Cells for Hematological Malignancies
Wagner, J. E., Bachanova, V., Betts, B., Brunstein, C. G., Cichocki, F. M., De For, T. E., Eaton, A., Hippen, K. L., Luo, X., Maakaron, J., McKenna, D. H. & Tolar, J.
NIH NATIONAL CANCER INSTITUTE (NCI)
5/5/23 → 4/30/28
Project: Research project
-
NK cells, their receptors, and cancer therapy
Miller, J. S., Bachanova, V., Basu, S., Brunstein, C. G., Cichocki, F. M., Felices, M., Geller, M. A., Grzywacz, B. J., Le, C. T., Luo, X., Starr, T., Walcheck, B., Warlick, E. D. & Weisdorf, D. J.
NIH NATIONAL CANCER INSTITUTE (NCI)
4/9/21 → 3/31/26
Project: Research project
-
-
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSEEXPANSION STUDY OF NKTR-255 AS A SINGLE AGENT IN RELAPSED OR REFRACTORYHEMATOLOGICAL MALIGNANCIES AND IN COMBINATION WITH DARATUMUMAB AS A SALVAGEREGIMEN FOR MULTIPLE MYELOMA
Bachanova, V. & Janakiram, M.
12/2/19 → 12/31/24
Project: Research project
-
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells
3/1/19 → 2/28/35
Project: Research project
-
Phase I/II Study of Nivolumab in Combination with Ruxolitinib in Relapsed or Refractory Hodgkin's LymphomaHodgkin???s Lymphoma
8/16/18 → 8/15/28
Project: Research project
-
-
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus
MILLENNIUM PHARMACEUTICALS, INC.
12/1/12 → 3/28/30
Project: Research project
-
Finished
-
-
-
A phase 1, open-label dose-escalation study of SEA-CD40 in adult patients with advancedmalignancies
3/1/17 → 2/28/21
Project: Research project
-
Multicenter Expanded Access Protocol of Allogeneic Epste
Bachanova, V. & Lazaryan, A.
5/20/16 → 1/1/22
Project: Research project
-
Novartis CCTL019A2205B; MT2015-16R: Long Term Follow-Up
NOVARTIS PHARMACEUTICALS CORPORATION
4/1/16 → 9/30/23
Project: Research project
-
-
-
-
Novartis CCTL019C2201; HM2015-13: A phase II, single arm
NOVARTIS PHARMACEUTICALS CORPORATION
4/10/15 → 12/14/22
Project: Research project
-
MT2015-12 : Phase 3 Randomized, Double-Blind, Placebo Co
Bachanova, V. & Lazaryan, A.
3/31/15 → 12/31/23
Project: Research project
-
HM2014-26 DT2219 immunotoxin for the treatment of relaps
12/19/14 → 12/30/20
Project: Research project
-
-
A Multicenter study of apheresis collection of periphera
NOVARTIS PHARMACEUTICALS CORPORATION
7/1/14 → 12/31/20
Project: Research project
-
-
Phase 2, Multicenter, Single-Arm Study to Evaluate the E
JANSSEN RESEARCH & DEVELOPMENT, LLC
6/18/12 → 9/30/17
Project: Research project
-
Host regulatory T cell depletion to enhance allogeneic N
AMERICAN SOCIETY OF HEMATOLOGY
7/1/11 → 12/31/14
Project: Research project
-
-
-
The Impact of Tyrosine Kinase Inhibitors (TKI) on Philad
NOVARTIS PHARMACEUTICALS CORPORATION
1/1/11 → 12/31/13
Project: Research project
-
-
-
-
-
MT2007-12: ALLOGENEIC NATURAL KILLER CELLS WITH RITUXIMAB IN PATIENTS WITH CD20
National Center for Research Resources
12/1/08 → 11/30/09
Project: Research project
-
-
Strategies to Increase Sensitivity of CLL Tumor Cells to
CANCER AND LEUKEMIA GROUP B FOUNDATION
8/1/08 → 7/31/09
Project: Research project
-
A phase II study of oral Panobinostat in adult patients
NOVARTIS PHARMACEUTICALS CORPORATION
6/15/08 → 1/30/11
Project: Research project
-
Natural Killer Cells Expansion and Maturation by Targeti
AMERICAN SOCIETY OF CLINICAL ONCOLOGY
7/1/07 → 1/1/09
Project: Research project
-